According to filings with the U.S. Securities and Exchange Commission, Diasome Pharmaceuticals is raising up to $15,555,620.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Robert Geho played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Diasome Pharmaceuticals
Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasomes Hepatocyte Targeting Platform reestablishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocytes natural regulatory functions.

To learn more about Diasome Pharmaceuticals, visit http://diasome.com/
Diasome Pharmaceuticals Linkedin Page: https://www.linkedin.com/company/diasome-pharmaceuticals-inc-/

Contact:
Robert Geho, Chief Executive Officer
216-444-7110
https://www.linkedin.com/in/robert-geho-106a755/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.